{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:25:01Z","timestamp":1792466701734,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunomodulatory (IMiD) agents like lenalidomide and pomalidomide induce the recruitment of IKZF1 and other targets to the CRL4CRBN E3 ubiquitin ligase, resulting in their ubiquitination and degradation. These agents are highly active in B-cell lymphomas and a subset of myeloid diseases but have compromised effects in T-cell lymphomas (TCLs). Here, we show that 2 factors determine resistance to IMiDs among TCLs. First, limited CRBN expression reduces IMiD activity in TCLs but can be overcome by newer-generation degrader CC-92480. Using mass spectrometry, we show that CC-92480 selectively degrades IKZF1 and ZFP91 in TCL cells with greater potency than pomalidomide. As a result, CC-92480 is highly active against multiple TCL subtypes and showed greater efficacy than pomalidomide across 4 in\u00a0vivo TCL models. Second, we demonstrate that ZFP91 functions as a bona fide transcription factor that coregulates cell survival with IKZF1 in IMiD-resistant TCLs. By activating keynote genes from WNT, NF-kB, and MAP kinase signaling, ZFP91 directly promotes resistance to IKZF1 loss. Moreover, lenalidomide-sensitive TCLs can acquire stable resistance via ZFP91 rewiring, which involves casein kinase 2\u2013mediated c-Jun inactivation. Overall, these findings identify a critical transcription factor network within TCLs and provide clinical proof of concept for the novel therapy using next-generation degraders.<\/jats:p>","DOI":"10.1182\/blood.2021014701","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T19:54:22Z","timestamp":1640202862000},"page":"2024-2037","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1"],"prefix":"10.1182","volume":"139","author":[{"given":"Wenchao","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9825-4241","authenticated-orcid":false,"given":"Geoffrey M.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, University Medical Center G\u00f6ttingen, Gottingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-5106","authenticated-orcid":false,"given":"Katherine A.","family":"Donovan","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-0071","authenticated-orcid":false,"given":"Rados\u0142aw P.","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-6217","authenticated-orcid":false,"given":"Tayla B.","family":"Heavican-Foral","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4139-0618","authenticated-orcid":false,"given":"Ajit J.","family":"Nirmal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Duffy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foster","family":"Powers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1344-5263","authenticated-orcid":false,"given":"Marcus Kenneth","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Y.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-2381","authenticated-orcid":false,"given":"Gongwei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1566-9308","authenticated-orcid":false,"given":"Salvia","family":"Jain","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-3281","authenticated-orcid":false,"given":"Ran","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Amaka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Trevisani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Donaldson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Hagner","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Summit, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"de Leval","sequence":"additional","affiliation":[{"name":"The Lausanne University Hospital, CHUV, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie, Universit\u00e9 Paris-Est, H\u00f4pital Henri-Mondor, INSERM U955, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeed","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-1706","authenticated-orcid":false,"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Summit, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Adelman","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Broad Institute of MIT and Harvard University, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2022033115284905600_B1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol."},{"issue":"20","key":"2022033115284905600_B2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"7","key":"2022033115284905600_B3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol."},{"issue":"10168","key":"2022033115284905600_B4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet."},{"issue":"10","key":"2022033115284905600_B5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2022033115284905600_B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/asheducation-2018.1.63","article-title":"Challenges and implications of genomics for T-cell lymphomas","volume":"2018","author":"Jacobsen","year":"2018","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"6168","key":"2022033115284905600_B7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science."},{"issue":"6168","key":"2022033115284905600_B8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science."},{"issue":"7559","key":"2022033115284905600_B9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature."},{"issue":"1","key":"2022033115284905600_B10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","article-title":"Small molecules co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models","volume":"175","author":"Minzel","year":"2018","journal-title":"Cell."},{"issue":"9","key":"2022033115284905600_B11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol."},{"key":"2022033115284905600_B12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2019.01299","article-title":"Ikaros zinc finger transcription factors: regulators of cytokine signaling pathways and CD4+ T helper cell differentiation","volume":"10","author":"Powell","year":"2019","journal-title":"Front Immunol."},{"issue":"13","key":"2022033115284905600_B13","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer."},{"issue":"2","key":"2022033115284905600_B14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"2022033115284905600_B15","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun."},{"issue":"1","key":"2022033115284905600_B16","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat Commun."},{"issue":"3","key":"2022033115284905600_B17","first-page":"3599","article-title":"ZFP91 zinc finger protein expression pattern in normal tissues and cancers","volume":"17","author":"Paschke","year":"2019","journal-title":"Oncol Lett."},{"issue":"6","key":"2022033115284905600_B18","first-page":"1217","article-title":"Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia","volume":"22","author":"Unoki","year":"2003","journal-title":"Int J Oncol."},{"issue":"23","key":"2022033115284905600_B19","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1111\/bph.14493","article-title":"Zinc finger protein 91 positively regulates the production of IL-1\u03b2 in macrophages by activation of MAPKs and non-canonical caspase-8 inflammasome","volume":"175","author":"Mi","year":"2018","journal-title":"Br J Pharmacol."},{"issue":"6","key":"2022033115284905600_B20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-01-828418","article-title":"CK1\u03b1 and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma","volume":"132","author":"Patil","year":"2018","journal-title":"Blood."},{"issue":"3","key":"2022033115284905600_B21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann Hematol."},{"issue":"9","key":"2022033115284905600_B22","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.4049\/jimmunol.0901284","article-title":"Ikaros is a regulator of Il10 expression in CD4+ T cells","volume":"183","author":"Umetsu","year":"2009","journal-title":"J Immunol."},{"issue":"20","key":"2022033115284905600_B23","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood."},{"issue":"12","key":"2022033115284905600_B24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","article-title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity","volume":"132","author":"Sievers","year":"2018","journal-title":"Blood."},{"issue":"7","key":"2022033115284905600_B25","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/bloodadvances.2020003431","article-title":"Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen","volume":"5","author":"Mo","year":"2021","journal-title":"Blood Adv."},{"issue":"13","key":"2022033115284905600_B26","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem."},{"issue":"4","key":"2022033115284905600_B27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia."},{"issue":"11","key":"2022033115284905600_B28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","article-title":"ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Nat Chem Biol."},{"issue":"4","key":"2022033115284905600_B29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/leu.2009.296","article-title":"Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis","volume":"24","author":"Matsuoka","year":"2010","journal-title":"Leukemia."},{"issue":"5","key":"2022033115284905600_B30","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0092-8674(88)90143-2","article-title":"The jun proto-oncogene is positively autoregulated by its product, Jun\/AP-1","volume":"55","author":"Angel","year":"1988","journal-title":"Cell."},{"issue":"5","key":"2022033115284905600_B31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0092-8674(92)90311-Y","article-title":"Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity","volume":"70","author":"Lin","year":"1992","journal-title":"Cell."},{"issue":"15","key":"2022033115284905600_B32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022033115284905600_B33","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica."},{"issue":"2","key":"2022033115284905600_B34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0378-1119(94)00717-7","article-title":"A widely expressed novel C2H2 zinc-finger protein with multiple consensus phosphorylation sites is conserved in mouse and man","volume":"152","author":"Saotome","year":"1995","journal-title":"Gene."},{"issue":"24","key":"2022033115284905600_B35","doi-asserted-by":"crossref","first-page":"36551","DOI":"10.18632\/oncotarget.9070","article-title":"Zinc finger protein 91 (ZFP91) activates HIF-1\u03b1 via NF-\u03baB\/p65 to promote proliferation and tumorigenesis of colon cancer","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget."},{"issue":"6","key":"2022033115284905600_B36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.2337\/db18-1236","article-title":"Identification of insulin-responsive transcription factors that regulate glucose production by hepatocytes","volume":"68","author":"Wang","year":"2019","journal-title":"Diabetes."},{"issue":"40","key":"2022033115284905600_B37","doi-asserted-by":"crossref","first-page":"30539","DOI":"10.1074\/jbc.M110.129551","article-title":"An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination","volume":"285","author":"Jin","year":"2010","journal-title":"J Biol Chem."},{"issue":"2","key":"2022033115284905600_B38","doi-asserted-by":"crossref","first-page":"e20201217","DOI":"10.1084\/jem.20201217","article-title":"ZFP91 is required for the maintenance of regulatory T cell homeostasis and function","volume":"218","author":"Wang","year":"2021","journal-title":"J Exp Med."},{"issue":"19","key":"2022033115284905600_B39","doi-asserted-by":"crossref","first-page":"e144318","DOI":"10.1172\/JCI144318","article-title":"ZFP91 disturbs metabolic fitness and antitumor activity of tumor-infiltrating T cells","volume":"131","author":"Wang","year":"2021","journal-title":"J Clin Invest."},{"issue":"8","key":"2022033115284905600_B40","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1073\/pnas.0911315106","article-title":"Close association of RNA polymerase II and many\u00a0transcription factors with Pol III genes","volume":"107","author":"Raha","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7527","key":"2022033115284905600_B41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13986","article-title":"Topologically associating domains are stable units of replication-timing regulation","volume":"515","author":"Pope","year":"2014","journal-title":"Nature."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/13\/2024\/1884249\/bloodbld2021014701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/13\/2024\/1884249\/bloodbld2021014701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:36:23Z","timestamp":1648766183000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/13\/2024\/483235\/Overcoming-IMiD-resistance-in-T-cell-lymphomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":41,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014701","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}